Skip to main content
. 2018 Dec 28;9(102):37700–37714. doi: 10.18632/oncotarget.26491

Figure 7. STRO-001 eradicates malignant bone marrow plasma cells and prolongs survival in MM.1S myeloma model.

Figure 7

NSG mice were inoculated with CD74-expressing MM.1S multiple myeloma cells. Treatment was started at day 11 and repeated once a week for 3 weeks with 3 mg/kg STRO-001 or 10 mg/kg STRO-001. Naïve control mice were not inoculated with tumor cells and did not receive treatment. (A) Kaplan-Meier survival curves in response to treatment. Note that 3 mg/kg STRO-001 is superimposed over 10 mg/kg STRO-001. (B) Quantification of hCD138+ cells in the bone marrow depicted as percent relative to vehicle control (set as 100% maximum) on days 32 and 129. Graph is shown as average values ± SEM.